 Fusion Proteins, bcr-abl
"Fusion Proteins, bcr-abl" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
| Descriptor ID |
D016044
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.500.500 D12.776.602.500.500.100 D12.776.624.664.500.100 D12.776.624.664.700.171.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fusion Proteins, bcr-abl".
Below are MeSH descriptors whose meaning is more specific than "Fusion Proteins, bcr-abl".
This graph shows the total number of publications written about "Fusion Proteins, bcr-abl" by people in this website by year, and whether "Fusion Proteins, bcr-abl" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 1 | 1 | 2 | | 1993 | 1 | 0 | 1 | | 1994 | 1 | 0 | 1 | | 1995 | 3 | 0 | 3 | | 1996 | 4 | 0 | 4 | | 1997 | 3 | 1 | 4 | | 1998 | 3 | 0 | 3 | | 1999 | 1 | 0 | 1 | | 2000 | 2 | 2 | 4 | | 2002 | 1 | 1 | 2 | | 2003 | 0 | 3 | 3 | | 2004 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 2 | 1 | 3 | | 2007 | 1 | 3 | 4 | | 2008 | 2 | 2 | 4 | | 2009 | 1 | 3 | 4 | | 2010 | 2 | 5 | 7 | | 2011 | 3 | 0 | 3 | | 2012 | 0 | 1 | 1 | | 2013 | 3 | 3 | 6 | | 2014 | 1 | 0 | 1 | | 2015 | 2 | 2 | 4 | | 2016 | 0 | 3 | 3 | | 2017 | 1 | 1 | 2 | | 2018 | 1 | 2 | 3 | | 2020 | 1 | 1 | 2 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Fusion Proteins, bcr-abl" by people in Profiles.
-
Kaumeyer B, Fidai S, Sukhanova M, Yap KL, Segal J, Raca G, Stock W, McNeer J, Lager AM, Gurbuxani S. MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia. Leuk Lymphoma. 2022 06; 63(6):1436-1444.
-
Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol. 2021 Jan 01; 7(1):42-50.
-
Elf SE. "All Our Wisdom is Stored in the Trees" - Degrading BCR-ABL with Berberis Vulgaris. Clin Cancer Res. 2020 08 01; 26(15):3899-3900.
-
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 04; 34(4):966-984.
-
Hantel A, Larson RA. Imatinib is still recommended for frontline therapy for CML. Blood Adv. 2018 12 26; 2(24):3648-3652.
-
Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer. 2018 04 02; 18(1):359.
-
Soderquist CR, Ewalt MD, Czuchlewski DR, Geyer JT, Rogers HJ, Hsi ED, Wang SA, Bueso-Ramos CE, Orazi A, Arber DA, Hexner EO, Babushok DV, Bagg A. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol. 2018 05; 31(5):690-704.
-
Reckel S, Gehin C, Tardivon D, Georgeon S, Kükenshöner T, Löhr F, Koide A, Buchner L, Panjkovich A, Reynaud A, Pinho S, Gerig B, Svergun D, Pojer F, Güntert P, Dötsch V, Koide S, Gavin AC, Hantschel O. Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase. Nat Commun. 2017 12 13; 8(1):2101.
-
Lu H, Villafane N, Dogruluk T, Grzeskowiak CL, Kong K, Tsang YH, Zagorodna O, Pantazi A, Yang L, Neill NJ, Kim YW, Creighton CJ, Verhaak RG, Mills GB, Park PJ, Kucherlapati R, Scott KL. Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer. Cancer Res. 2017 07 01; 77(13):3502-3512.
-
Parilla M, Venkataraman G. The thin line between CML and CMML. Blood. 2017 04 27; 129(17):2456.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|